Replies to post #13516 on GT Biopharma Inc (GTBP)

[JoniCash]

OXS-1550 uses a proprietary immunoconjugate platform technology, as a treatment for leukemia and other blood-born cancers. What sets OXS-1550 apart from other treatments, such as chemotherapy, is that it is designed to specifically target and kill cancer cells minimizing damage to normal tissues.

[SmallCapStockGuy]

"expected in 2H ‘18."

Closing in on that VERY QUICKLY